Thin film drug manufacturers have experienced rapid revenue growth over the past five years, and this trend is expected to continue over the five years to 2019 as the patent cliff enables more generic drugs to enter the market. Further, over the five-year period, many thin film drug manufacturers will focus on developing a drug pipeline that encompasses more therapeutic classes, such as drugs that treat respiratory-related ailments.
This industry manufactures dissolving films or oral drug strips that are used to administer drugs via absorption in the mouth or via the small intestines. Thin film use has emerged as an advanced drug delivery method that makes drugs easy to swallow without water and improves dosing accuracy. Additionally, offering a drug in thin film form can extend product life cycles for pharmaceutical companies that have expiring drug patents and may be exposed to generic competition.
The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecast, growth rates and an analysis of the industry key players and their market shares.